Company intelligence / Profile preview
Oxford BioTherapeutics
Oxford, England, United Kingdomoxfordbiotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
OBT has three programs in clinical development across the US and Europe. The lead asset, OBT076, an ADC with a dual mechanism of action ("primer" for immune system + direct targeting), is currently in Phase I/Ib trials. The company claims a pipeline of over thirty clinical-stage assets through partnerships and more than ninety partnered assets overall. No published pivotal efficacy data yet available as of May/June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADC)Immuno-oncology therapiesT-cell engagers (TCE)CAR-T cell therapiesBispecific antibodiesRadiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Oxford BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxford BioTherapeutics.